(60) utilized next generation sequencing (NGS) and computational analysis to demonstrate that miR-23b-3p, acting as a tumor suppressor, can inhibit tumor Gln metabolism by targeting GLS1, thereby enhancing the sensitivity of liver tumor cells to sorafenib. The gene discussed is GLS; the disease is neoplasm.